EMPRESS-MI
Research type
Research Study
Full title
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI): a multi-centre, randomized, placebo-controlled trial
IRAS ID
302654
Contact name
Colin Berry
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Eudract number
2021-006086-38
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Heart attacks are a common health problem in the United Kingdom. A proportion of people who have a heart attack will develop a complication called heart failure. This is when the damage to the heart muscle means that the heart is not able to pump blood around the body as effectively as it should. It can cause symptoms such as breathlessness, fluid retention and reduced exercise capacity. The development of heart failure also increases the risk of dying in the years following a heart attack.
We aim to compare empagliflozin to standard care in 100 patients with evidence of muscle damage after a heart attack to prevent the development of heart failure. Patients will take empagliflozin or placebo for 6 months alongside usual medication. The effect of the medication will be assessed using a magnetic resonance imaging (MRI) scanner at the start of the trial and at 6 months to look at the heart muscle and the pump function in detail. We will also measure blood tests which are markers of heart muscle damage.
We aim to show that empagliflozin is better than the current standard of care at slowing the decline in heart muscle contraction and increase in heart chamber size that may occur in patients with heart muscle damage following a heart attack.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
22/NE/0030
Date of REC Opinion
24 Feb 2022
REC opinion
Favourable Opinion